Pacira’s Exparel Problems: CR Letter Stops New Indication
FDA finds issues with a supplemental application to use the pain treatment for nerve block shortly after Pacira gives 2015 financial guidance.
FDA finds issues with a supplemental application to use the pain treatment for nerve block shortly after Pacira gives 2015 financial guidance.